LONDON: An international clinical trial testing a novel cancer immunotherapy, which may prevent skin cancer from recurring, has recruited its first patient in Britain this week.
The mRNA-based technology, the vaccine tech used for some COVID vaccinations, is aimed at people who have already had high-risk melanomas – the most serious form of cancer – removed.
For the trial, University College London Hospitals (UCLH) doctors are giving it alongside another drug, pembrolizumab or Keytruda, that also helps the immune system kill cancer cells.
